Lucid Diagnostics Inc.
LUCD Healthcare Medical Devices
Lucid Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 26.7%, EPS was flat, free cash flow fell 7.04% and total debt fell 7.11%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow LUCD
Lucid Diagnostics Inc. (LUCD) P/E ratio
Lucid Diagnostics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| QTRX Quanterix Corporation compare | n/m |
| HYPR Hyperfine, Inc. compare | n/m |
| OWLT Owlet, Inc. compare | n/m |
| SERA Sera Prognostics, Inc. compare | n/m |
| MXCT MaxCyte, Inc. compare | n/m |
| LUCD Lucid Diagnostics Inc. | n/m |
| ZOMDF Zomedica Corp. compare | n/m |
| LUNG Pulmonx Corporation compare | n/m |
| APYX Apyx Medical Corporation compare | n/m |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)